Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

(2020) Marie José Kersten et al.   HAEMATOLOGICA

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

(2020) Paul J. Bröckelmann et al.   JAMA Oncology

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

(2020) Fathima Zumla Cader et al.   NATURE MEDICINE

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma

(2020) Pamela Blair Allen et al.   BLOOD

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

(2020) Sarah Reinke et al.   BLOOD

Elusive sentinels at the Hodgkin checkpoint

(2020) Sheren Younes et al.   BLOOD

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma

(2019) Deborah M Stephens et al.   BLOOD

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

(2019) Alison J. Moskowitz et al.   BLOOD

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial

(2018) Andrea Gallamini et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

(2018) David J. Straus et al.   BLOOD

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

(2018) Peter D Cole et al.   LANCET ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma

(2015) Robert Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types

(2015) Peter W. M. Johnson   HEMATOLOGICAL ONCOLOGY

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

(2015) John Radford et al.   NEW ENGLAND JOURNAL OF MEDICINE

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma

(2014) Ryan D. Gentzler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunological off-target effects of standard treatments in gastrointestinal cancers

(2013) A. G. Duffy et al.   ANNALS OF ONCOLOGY

Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT

(2013) S Akhtar et al.   BONE MARROW TRANSPLANTATION

Farnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2013;98(1):31-40

(2013) G. Kleiner et al.   HAEMATOLOGICA

Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

(2012) R. Devillier et al.   HAEMATOLOGICA

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation

(2011) Jacob P. Smeltzer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

(2011) C. H. Moskowitz et al.   BLOOD

Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

(2011) Heidi Mocikova et al.   LEUKEMIA & LYMPHOMA

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

(2010) A. J. Moskowitz et al.   BLOOD